Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay
Chunlong Ma(University of Arizona), Jun Wang(Rutgers Sexual and Reproductive Health and Rights), M. Sacco(University of South Florida), Julia A. Townsend(University of Arizona), Yanmei Hu(University of Arizona), Maura V. Gongora(University of South Florida), Yan Xiang(Sichuan University), Tommy Szeto(University of Arizona), Antonios Kolocouris(National and Kapodistrian University of Athens), Fushun Zhang(The University of Texas at San Antonio Health Science Center), Michael T. Marty(University of Arizona), Yu Chen(University of South Florida), Xiujun Zhang(Tianjin University of Traditional Chinese Medicine), Zilei Xia(University of Arizona), Mandy Ba(University of Arizona), George Lambrinidis(National and Kapodistrian University of Athens), Xiangzhi Meng(University of California, Los Angeles)
Cited by 200
Related Papers
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M <sup>pro</sup> and cathepsin L
|Science Advances|2020|400
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
|Nature|2021|216
The <i>in vitro</i> antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
|Emerging Microbes & Infections|2021|190
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
|Journal of Medicinal Chemistry|2021|168
Establishing <scp>CRISPR</scp>/Cas13a immune system conferring <scp>RNA</scp> virus resistance in both dicot and monocot plants
|Plant Biotechnology Journal|2019|161